Background/Aims: Preventing cell metastasis is an effective therapeutic strategy to treat osteosarcoma and improve prognosis. Statins have been found to have anticancer effects in addition to their cholesterol-lowering action. As a new target of statins, cysteine-rich 61 (CYR61) was recently identified to promote cell migration and metastasis in osteosarcoma. However, the underlying mechanisms mediating the regulation of CYR61 expression by statins remain unknown. Methods: Human osteosarcoma cell lines MG63 and SaOS2 were used to clarify the effect of lovastatin on CYR61 expression. Real-time PCR was performed to detect mRNA or microRNA (miRNA) levels and western blot was performed to detect protein levels. Cell invasive ability was determined using Transwell assays. Lentivirus encoding CYR61 cDNA or sterol regulatory element-binding protein 2 (SREBP-2) shRNA was used to upregulate CYR61 expression or downregulate SREBP-2 expression. Binding of the CYR61 3' untranslated region (UTR) and miR-33a was analyzed by luciferase reporter assay. Results: We found that lovastatin treatment decreased CYR61 expression, inhibited cell invasion and altered epithelial-to-mesenchymal-transition (EMT)-related protein expression, while CYR61 overexpression abolished the effect of lovastatin. Moreover, lovastatin increased the expression of SREBP-2 and miR-33a, which were then downregulated by SREBP-2 silencing. Bioinformatics analysis indicated that the CYR61 3′UTR harbored a potential miR-33a binding site and luciferase reporter assay demonstrated that CYR61 was a target of miR-33a in osteosarcoma cells. Furthermore, miR-33a could inhibit cell invasion and alter EMT-related protein expression. SREBP-2 silencing or miR-33a inhibitor upregulated CYR61 expression and reversed the effects of lovastatin on cell invasion and EMT-related proteins. Conclusion: Our findings suggest lovastatin suppresses osteosarcoma cell invasion through the SREBP-2/ miR-33a/CYR61 pathway.
Introduction
Osteosarcoma is the most common primary tumor of bone in young people and is characterized by a highly malignant and metastatic potential. Despite recent advancements in the diagnosis and treatment of osteosarcoma, the prognosis and 5-year survival rate of these patients remains poor due to its recurrence and metastasis [1] .
Cysteine-rich 61 (CYR61) is a member of the cyr61/CTGF/Nov family [2] , whose proteins are associated with the extracellular matrix and cell surface [3] . CYR61 has been reported to mediate cell adhesion, proliferation, and differentiation and has been linked to tumor development [3] [4] [5] . CYR61 was found to be overexpressed in breast cancer [6] , glioma [7] and pancreatic cancer [8] , and downregulated in prostate cancer [9] , rhabdomyosarcoma [10] and non-small-cell lung carcinoma [11] , suggesting it may play different roles depending on the type of cancer. Recent studies have shown that aberrant expression of CYR61 is associated with osteosarcoma aggressiveness and metastatic potential [12] . CYR61 downregulation reduces osteosarcoma cell metastatic activity and recombinant CYR61 promotes the epithelial-to-mesenchymal transition (EMT) process and metastasis in osteosarcoma [13, 14] . Interestingly, CYR61 has also been identified as a target of statins and its expression was suppressed by statins in osteosarcoma cells [13] . As inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, statins block the conversion of HMG-CoA into mevalonate and are widely used to lower cholesterol. Recently, statins have also been suggested to have anticancer effects by regulating multiple signaling pathways [15] [16] [17] . However, the underlying mechanisms mediating statin regulation of CYR61 expression remain unknown.
Sterol regulatory element-binding proteins (SREBPs, including SREBP-1 and -2) are a family of basic helix-loop-helix leucine zipper transcription factors that regulate cholesterol and fatty acid synthesis [18] . They are membrane-bound proteins and must undergo proteolytic cleavage to generate active nuclear forms [18] . Specifically, SREBP-2 is involved in cholesterol synthesis and is regulated by intracellular cholesterol levels [19] . Low cholesterol levels likely caused by statins have been thought to activate SREBP-2 [20] . The human SREBP-2 gene is located on chromosome 22 and also encodes a microRNA (miRNA) within its intron, miR-33a. MiRNAs are small, non-protein-coding RNAs which act as key mediators in cancer by binding to specific regions in the 3′ untranslated region (UTR) of target mRNA and inhibiting translation or promoting mRNA degradation. MiR-33a is cotranscribed with SREBP-2 and is induced by statins [21] . In addition to controlling critical aspects of cholesterol homeostasis [21] , miR-33a was recently shown to function as a tumor suppressor [22] [23] [24] [25] [26] . However, whether miR-33a is involved in the regulation of CYR61 expression by statins remains unclear.
Here, we used lovastatin to explore the mechanism mediating the anticancer effect of statins in osteosarcoma. Our data identified CYR61 as a new target gene of miR-33a in osteosarcoma and connected the SREBP-2/miR-33a/CYR61 pathway to lovastatin suppression of osteosarcoma cell invasion.
Materials and Methods

Cell culture
Human osteosarcoma cell lines (MG63 and SaOS2) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured [23] with 10% fetal calf serum (FCS, Invitrogen, Waltham, MA, USA) at 37°C with 5% CO 2 . Lovastatin (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in DMSO and used to treat the cells.
Real-time PCR
Total RNA from cells was extracted with Trizol reagent (Invitrogen) and converted into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturer's instructions. Real-time PCR was performed to detect mRNA and miRNA expression using a PowerUp SYBR Green Master Mix (Thermo Fisher Scientific Inc.) and miRNA Q-PCR Detection Kit (GeneCopoeia, Rockville, MD, USA), respectively. The primers used were as follows: CYR61, 5'-CTCGCCTTAGTCGTCACCC-3' (forward) and 5'-CGCCGAAGTTGCATTCCAG-3' (reverse); SREBP-2, 5'-CCTGGGAGACATCGACGAGAT-3' (forward) and 5'-TGAATGACCGTTGCACTGAAG-3' (reverse); β-actin, 5'-CACTCTTCCAGCCTTCCTTC-3' (forward) and 5'-GTACAGGTCTTTGCGGATGT-3' (reverse); and U6, 5'-GCTTCGGCAGCACATATACTAAAAT-3' (forward) and 5'-CGCTTCACGAATTTGCGTGTCAT-3' (reverse). β-actin or U6 gene was used as an internal control for mRNA or miRNA, respectively, and relative amounts of RNA were calculated by the 2 -△△Ct method.
Western blot
Cells were lysed in cold RIPA lysis buffer (Beyotime, Shanghai, China) and proteins in the supernatants were quantified. After separation by 10% SDS-PAGE, proteins were transferred onto polyvinylidene difluoride membranes (Life Technologies, Carlsbad, CA, USA). The blots were blocked with 10% nonfat milk in PBS and then probed with anti-CYR61 (Abcam, Cambridge, MA, USA), anti-SREBP-2 (Santa Cruz, Dallas, TX, USA), anti-E-cadherin, anti-N-cadherin or anti-β-actin antibody (all from Cell Signaling Technology, Inc., Danvers, MA, USA) for 1 h at room temperature. After washes, the blots were incubated with HRP-linked secondary antibodies and observed using an enhanced chemiluminescence kit (Pierce Chemical, Rockford, IL, USA). Protein levels were normalized to β-actin.
Transwell assay
Transwell assays were performed to determine cell invasive ability using BD Falcon cell culture inserts (BD Biosciences, San Jose, CA, USA) coated with Matrigel (BD Biosciences). After different pretreatments, approximately 1 × 10 4 cells in 200 μL serum-free medium were seeded in the upper chamber, and 800 μl of cell culture medium with 10% FCS were placed in the lower chamber. After incubation at 37°C in 5% CO 2 for 24 h, cells in the upper compartment were removed with a cotton bud and those in the lower compartment were fixed in 10% formalin and stained with 0.05% crystal violet. The invading cells were counted using a microscope in four randomly selected fields.
Cell transfection
The recombinant lentivirus encoding the full-length CYR61 gene was constructed by Hanbio (Shanghai, China) using pHBLV-CMVIE-IRES-Puro lentiviral vectors. The lentivirus encoding SREBP-2 shRNA was purchased from OriGene (Rockville, MD, USA). The empty pHBLV-CMVIE-IRES-Puro lentiviral vectors (Hanbio) and Lenti-shRNA Control Particles (OriGene) were used as negative controls. For stable overexpression of CYR61 or knockdown of SREBP-2, MG63 and SaOS2 cells were infected with the corresponding lentivirus for 36 h and stable clones selected by puromycin (10 μg/mL) for 2 weeks.
For upregulation and downregulation of miR-33a, 25 nM miR-33a mimics and an miR-33a inhibitor (Ambion, Austin, TX, USA), respectively, were used to transfect MG63 and SaOS2 cells with Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions.
Cell viability assay
MTT assays were used to examine cell viability. MG63 and SaOS2 cells (10000 cells/per well) treated with or without 10 µM lovastatin were plated in a 96-well plate and incubated at 37°C in 5% CO 2 for 24 h. MTT solution (20 μL of 5 mg/ml; Sigma-Aldrich) was then added to each well for 4 h. The supernatant was removed and 100 μL of DMSO were added. Absorbance was detected at 570 nm with a Microplate Reader (Bio-Rad, Hercules, CA, USA).
Luciferase reporter assay
The CYR61 3′UTR was amplified from MG63 cells and cloned into pmirGLO Vector (Promega, Madison, WI, USA) as pmir-wt-CYR61. Mutations were introduced at potential miR-33a binding sites to construct pmir-mut-CYR61 using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA Huang et al.: miR-33a Mediates the Anti-Tumor Effect of Lovastatin cells were co-transfected with the pmir-wt-CYR61 vector and miR-33a mimics or mimic-negative control (NC), or with the pmir-mut-CYR61 vector and miR-33a mimics or NC. After transfection for 48 h, luciferase activities were determined using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions.
Statistical analysis
Data are presented as means ± standard deviation (SD). Differences between two samples were analyzed for significance using Student's t-test. Statistical comparisons of more than two groups were performed using one-way analysis of variance with Bonferroni's post hoc test. P values less than 0.05 were considered statistically significant.
Results
CYR61 mediates the effect of lovastatin on osteosarcoma cell invasion and EMT-related protein expression
To clarify the effect of lovastatin on the expression of CYR61 in osteosarcoma cells, realtime PCR and western blots were performed after lovastatin treatment. As shown in Fig.  1A , 1-10 μM lovastatin treatment markedly decreased CYR61 mRNA expression and protein levels in MG63 and SaOS2 cells in a dose-dependent manner. To validate the role of CYR61 on the antitumor effect of lovastatin, lentivirus with CYR61 encoding sequence (Lv-CYR61) was constructed and transduced into MG63 and SaOS2 cells (Fig. 1B) . After lovastatin treatment, CYR61 mRNA and protein levels were significantly higher in Lv-CYR61-transduced cells than in control cells without transduction ( Fig. 1C and D) . We then evaluated the effect of lovastatin on cell invasion and EMT-related protein expression and the role of CYR61 in the function of lovastatin. As shown in Fig. 1E , lovastatin treatment reduced cell invasive capability in a dose-dependent manner, while CYR61 overexpression abolished the effect of lovastatin and increased cell invasiveness. Cell viability was also examined (Fig. 1F) to exclude the effect of lovastatin on cell motility [27] . Lovastatin treatment also induced the expression of epithelial marker E-cadherin, but repressed mesenchymal marker N-cadherin, and these effects were reversed by Lv-CYR61 (Fig. 1G) .
Lovastatin upregulates miR-33a levels by inducing SREBP-2 expression
To explore the mechanism by which lovastatin induces CYR61 expression, we first determined whether lovastatin affected the expression of SREBP-2 and miR-33a. As shown in Fig. 2A and B, lovastatin increased the expression of SREBP-2 and miR-33a in a dosedependent manner. Western blot assay showed that lovastatin also increased the mature form (~50-68 kDa) of SREBP-2 (Fig. 2C) . Furthermore, we suppressed SREBP-2 expression using lentivirus-mediated RNA interference. The results showed that SREBP-2 silencing significantly decreased SREBP-2 mRNA levels as well as protein levels of the precursor and mature forms of SREBP-2 with or without lovastatin treatment (Fig. 2D-G) . MiR-33a expression was also downregulated by SREBP-2 silencing (Fig. 2F) , suggesting that lovastatin upregulates miR-33a levels by inducing SREBP-2 expression.
CYR61 is a target gene of miR-33a in osteosarcoma
Bioinformatics analysis indicated that the CYR61 3′UTR harbored a potential miR-33a binding site, implying CYR61 is a target gene of miR-33a. To clarify this, miR-33a mimics were used to increase the miR-33a level (Fig. 3A) , and a luciferase reporter vector with a wild-type or mutant CYR61 3'UTR was generated to test the interaction between miR-33a and CYR61 (Fig. 3B) . The results of luciferase reporter assays showed that miR-33a mimics significantly decreased luciferase activity in cells transfected with the wild-type CYR61 3′UTR vector, but not in cells transfected with the mutant CYR61 3′UTR vector (Fig. 3C) . Moreover, miR-33a led to significantly reduced CYR61 mRNA and protein expression compared with the control (Fig. 3D and E ). These results demonstrate that CYR61 is a target of miR-33a in osteosarcoma cells. 
Discussion
In this study, we showed that lovastatin induced the co-expression of SREBP-2 and miR33a in osteosarcoma cells. MiR-33a inhibited cell invasion and altered EMT-related protein expression by targeting CYR61. These results suggest a potential mechanism underlying the anticancer effect of statins.
In addition to their wide use as cholesterol-lowering agents, statins are currently under consideration as potential drugs for cancer therapy [28] . Anticancer effects of statins have been reported in a variety of cancer types including osteosarcoma [29] [30] [31] . Although RhoAmediated signaling has been shown to be involved in simvastatin-induced apoptosis and atorvastatin-reduced invasion of osteosarcoma cells [17, 32] , Olivia et al. identified CYR61 as a new target of atorvastatin that was independent from RhoA signaling [13] . CYR61 has been reported to be an oncogene and is associated with osteosarcoma aggressiveness and metastatic potential [11] .
Lovastatin is the first statin to be approved by the US FDA as a cholesterol-lowering drug, but its effects on osteosarcoma development have yet to be thoroughly evaluated. Here, we showed that lovastatin treatment markedly decreased CYR61 expression levels and that CYR61 overexpression abolished the effect of lovastatin on cell invasion and EMTrelated proteins, suggesting that CYR61 mediates the anticancer effects of lovastatin on osteosarcoma cells.
MiR-33a is located within an intron of the SREBP2 gene and has been found to mediate the hepatotoxic effects of statins. Bioinformatics analysis showed that CYR61 is a potential target of miR-33a. Therefore, we proceeded to investigate whether miR-33a mediates the regulation of lovastatin on CYR61. As the host gene of miR-33a, SREBP-2 is activated in response to the reduction in hepatic cholesterol content as well as by statins [19] . Activated SREBP-2 in its mature form then enters the nucleus and activates transcription of genes involved in cholesterol homeostasis [18] . Our study showed that lovastatin not only increased the mature form of SREBP-2, but also increased total SREBP-2 expression. Considering that sterol regulatory elements are present in its promoter [33] , SREBP-2 may induce its own expression in a manner similar to SREBP-1 [34] . This is also consistent with results showing that miR-33a expression was downregulated by SREBP-2 shRNA.
MiR-33a was recently identified as a tumor suppressor in melanoma, non-small cell lung cancer, and breast cancer by targeting multiple genes [22] [23] [24] . Here, we found that miR-33a could regulate CYR61 by binding to its 3'-UTR in osteosarcoma cells. CYR61 plays an important role in osteosarcoma invasion, EMT, and metastasis via a signal transduction pathway that involves αvβ5 integrin, Raf-1, MEK, ERK, and Elk-1 [13, 14] . The suppressive effect of miR-33a on osteosarcoma cell invasion and EMT-related protein expression, similar to the effect of lovastatin, was also mediated by CYR61. SREBP-2 silencing or an miR-33a inhibitor significantly attenuated the effects of lovastatin on cell invasion and EMT-related proteins, suggesting that the SREBP-2/miR-33a/CYR61 pathway mediated the anticancer effect of statins in osteosarcoma. Interestingly, CYR61 was also found to activate the SREBP pathway and upregulate fatty acid synthase protein expression in breast cancer cells [35] . There may be a feedback loop between SREBP-2 and CYR61 or crosstalk with fatty acid metabolism that is worth further investigation.
Conclusion
Our data demonstrate that lovastatin regulates CYR61 expression by activating SREBP-2 and inducing miR-33a expression. This pathway mediates the suppressive effects of lovastatin on osteosarcoma cell invasion. This study provides a molecular basis for the use of statins in cancer therapy and suggests potential targets for osteosarcoma treatment.
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